Business in Brief: Pharma Shares Take Tel Aviv Stock Exchange Higher
Shari Arison sells Israeli salt monopoly to Fortissimo fund ■ Five companies weighing bids to set up small-business lender
Teva Pharmaceutical
Business in Brief: Tel Aviv Shares Post Fourth Straight Rise
Teva CEO Schultz says company’s key U.S. generics market has stabilized ■ Naphtha to make tender offer for Isramco ■ Current, former Aeronautics executives suspected of insider trading
Business in Brief: Teva Threatened With Strike at Main Plant for Making Top-selling Copaxone Drug
Two reach plea deal in fraud case ■ Brookland’s controlling shareholder quits ■ Radware buys Indian company ■ stocks extend gains
Business in Brief: Tel Aviv Shares Quietly Mark End of Stormy Year
Teva said to be in talks to sell Oncotest diagnostics unit ■ Africa Israel bailout collapses as Moti Ben-Moshe asks for deposit back
Business in Brief: Dollar at Two-year High Versus Shekel
Teva shareholders demand company sue U.S. employees over role in alleged cartel ■ Tel Aviv shares ride back of Wall Street rebound as China trade fears ease
Teva Suspected of Being Part of a Cartel in U.S. Engaged in Price-fixing and Dividing Market for Generics
The Israeli generics manufacturer is one of 16 drug firms under investigation over purported price-fixing involving 300 medications
Business in Brief: Teva Patent Dispute With Swiss Firm Reaches U.S. Supreme Court
Warburg Pincus in talks with Allied Holding to sell it Leumi Card stake ■ Corning reportedly in talks to buy Israel’s Teldor Cables ■ Taptica shares plunge after CEO quits following fraud ruling ■ Tel Aviv shares fall as optimism on U.S.-China trade ebbs
Teva Shares Rally, Forecast 'Very Strong Launch' for Long-awaited Ajovy Migraine Treatment
The company added that it expected to launch its generic version of the best-selling EpiPen allergy treatment in the current quarter
Business in Brief: Teva Leads Sharp Rise in Tel Aviv Shares
Little-known Krausz Metal Industries fetches $135 million from U.S. buyer ■ Boards approve merger of JOEL into parent company Equital ■ Israel Chemicals profit rose 16.5% in quarter
Teva Raises 2018 Earnings Outlook, Says 'Very Good Signs' of New Drug Launch
Teva has been counting on its long-awaited migraine drug to revive its fortunes after suffering a drop in revenue
Teva Loses Negotiations Over New Migraine Drug, Stock Falls 5 Percent
The Israeli pharmaceutical company's new drug will not be covered by U.S. prescription benefits manager, though it's competitors will.
Lilly Defeats Teva Patent Lawsuits Over Migraine Drug
Teva was trying to block its competitor from bringing its migraine drug Emgality to market in the United States
Business in Brief: Foamix Soars on Trials for Acne Treatment
Opko chief, ex-Teva chairman Phillip Frost charged with share manipulation in U.S. ■ Generation Capital takes 50% stake in power plant operator Rapac Energy ■ TASE ends lower after long holiday weekend
Business in Brief: Israeli Government Gained $275 Million by Delaying Leumi Share Sale
Teva offers to buy back $400 million in bonds ■ RADA cashes in on drone-threat fears ■ TASE closes in the red, dragged down by Wall Street
FDA Approves Teva's Generic Version of Mylan's EpiPen
Teva Pharmaceutical's version of Mylan NV's EpiPen to provide 'lower-cost option' for patients 'living with severe allergies,' FDA commissioner says
Warren Buffett Buys $60 Million Worth of Teva in the Dip
Berkshire Hathaway also massively invested more in Goldman Sachs and Apple
Teva Shares Tumble After Company Disappoints Markets
The pharmaceutical company is in a $28.4 billion debt. Analysts says the company still lacks growth drivers
Teva Surprises With Better-than-expected First Quarter
Trouble drugmaker offers rosier outlook for rest of year, despite delay in approval for key migraine treatment
The Ticker: Buffett Says Decision to Buy Teva Stake Was Taken by Deputies
Elsztain enlists unions to help block sale of Clal Insurance ■ Medical-marijuana shares get lift as lawmakers express support for exports ■ Shares end mixed as bank stage powerful rally
Opinion Israel Needs to Find a Better Financial Role Model Than America
U.S. President Trump’s obsession with the stock market as a gauge of his success augurs ill, and Israel needs to rethink its own strategy
Business in Brief: Teva Unfazed as U.S. Approves Second Generic Rival for Copaxone
Gilat finally swings to profit ■ Leumi turns bearish on Leviathan ■ Stocks end mixed
Four Top Execs Cost Teva $31 Million in 2017, Even as It Posted Huge Losses
Nearly half went to three managers leading company during failed Actavis acquisition
The Ticker: Shares Slump on Teva and Wall Street
Police raid Shapir offices, question four ■ Fattal Hotels cuts valuation on IPO by 25% ■ Starwood Retail files to sell a billion shekels in bonds in Tel Aviv
Teva Reports Massive $11.6 Billion Loss, Predicts Weak 2018
Shares tumble amid concerns that turnaround with the company's new CEO may take longer than expected
Teva Files to Raise $5 Billion in Debt Issue
Business in Brief | Bezeq to shuffle board; Noble to cut stake in Tamar gas field; Dorit Wertheim sells Aloni Hetz stake to brother; Biomed and insurance stocks fall
Teva Plans to Raise $5 Billion as It Deals With Massive Debt Burden
The pharmaceutical giant pushes ahead with global overhaul and major cutbacks
The Ticker: Leumi to Sell 15% of U.S. Unit to Two Strategic Investors
Teva reports disappointing results from asthma drug trials ■ Discount transfers 5% Cellcom stake to two Elsztain allies to conform with law ■ Delek’s Ithaca unit sells oil field to help pay down debt ■ Teva, Israel Chemicals give a lift to Tel Aviv shares
Business in Brief: Institutions to Help Fund Energean Gas Field
Starboard ups ante in Mellanox fight; Yahak bids for Equital shares; stocks stung by Teva
The Ticker Business in Brief: Teva Directors to Take Pay Cut
Israel selling $2 billion in dollar bonds; Antitrust decision on Mizrahi-Union tie-up needs more time; China angst sends stocks lower
Teva, Unions Reach Pact on Severance Terms for Administrative Staff
Agreement covers employees who agree to leave voluntarily